Not sure where to start? Try searching for your diagnosis above or visit the "Conditions" section.
Curated scientific studies about autoimmune diseases.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
A 2025 randomized trial published in Clinical Rheumatology found that baricitinib, a JAK1/2 inhibitor already approved for rheumatoid arthri...
Read More — BASICS Trial: Baricitinib 4 mg Significantly Reduces Skin Fibrosis in Systemic Sclerosis »A phase 3 clinical trial found that inebilizumab, a CD19-targeting antibody that depletes B cells, significantly improved daily functioning...
Read More — Inebilizumab Significantly Improves Function in Generalized Myasthenia Gravis: Phase 3 MINT Trial »For the first time, a drug has shown a statistically significant ability to slow disability progression in people with nonrelapsing secondar...
Read More — Tolebrutinib Reduces Disability Progression in Nonrelapsing Secondary Progressive Multiple Sclerosis: Phase 3 HERCULES Trial »A large phase 3 clinical trial found that upadacitinib, an oral JAK inhibitor, helped significantly more patients with giant cell arteritis...
Read More — JAK Inhibitor Upadacitinib Achieves Superior Sustained Remission in Giant Cell Arteritis Phase 3 Trial »Five-year extension data for bimekizumab (Bimzelx) show that nearly 50% of patients with ankylosing spondylitis maintained an ASAS40 respons...
Read More — Bimekizumab Maintains Strong Efficacy Across Five Years in Ankylosing Spondylitis »A comprehensive 2025 review summarizes emerging targeted therapies for Graves' disease that go beyond antithyroid drugs, radioiodine, and su...
Read More — Emerging Targeted Immunotherapies Show Promise for Graves' Disease Beyond Standard Antithyroid Drugs »A 2025 narrative review in Brain Sciences examines ADEM in adults, covering the full range of infectious triggers including COVID-19, and th...
Read More — Updated Review Brings New Clarity to ADEM Triggers, Diagnosis, and Treatment in Adults »The ALLEGRO-LT Phase 3 extension study confirms that ritlecitinib (Litfulo) maintains meaningful hair regrowth at three years in adults and...
Read More — Three-Year Data Confirms Sustained Hair Regrowth with Ritlecitinib for Alopecia Areata »A 2025 review in Arthritis and Rheumatology outlines a wave of clinical trials testing targeted, disease-modifying therapies for antiphospho...
Read More — Emerging Targeted Therapies for Antiphospholipid Syndrome Go Far Beyond Blood Thinners »For the first time ever, two Phase III clinical trials have shown a statistically significant reduction in Sjögren's disease activity....
Read More — First-Ever Phase III Trials Deliver Meaningful Results for Sjögren's Disease with Ianalumab »A Phase II multicenter trial published in The New England Journal of Medicine found that tulisokibart, a novel monoclonal antibody targeting...
Read More — ARTEMIS-UC Phase II Trial: Tulisokibart (Anti-TL1A) Achieves Clinical Remission in Moderate to Severe Ulcerative Colitis »